Skip to main content
PLOS Biology logoLink to PLOS Biology
. 2025 Aug 7;23(8):e3003312. doi: 10.1371/journal.pbio.3003312

An arginine switch drives the stepwise activation of β-arrestin by CXCR7

Jeong Seok Ji 1,#, Yaejin Yun 1,#, Tomasz Maciej Stepniewski 2,3,4,#, Hye-Jin Yoon 1, Kyungjin Min 1, Ji Young Park 5, Chiwoon Chung 5, Miguel Dieguez Eceolaza 2, Ka Young Chung 5, Jana Selent 2,*, Hyung Ho Lee 1,*
Editor: Carole A Parent6
PMCID: PMC12331092  PMID: 40773476

Abstract

β-arrestins (βarrs) play a crucial role in regulating G protein-coupled receptor (GPCR) signaling and trafficking. Canonically, interactions of βarr with the phosphorylated intracellular GPCR-tail induce a multi-step conformational transition that results in the activation of βarr. Depending on the specific interaction pattern with the receptor, βarrs adopt multiple conformational states, each tightly linked to a specific functional outcome of βarr recruitment. Despite its physiological relevance, the structural determinants of βarr activation remain poorly understood. Using a combination of molecular dynamics simulations, biochemical and cell-based experiments, we reveal how specific interactions with a chemokine receptor 7 (CXCR7) promote the unbinding of the βarr2 C-tail—a crucial step in arrestin activation. Importantly, we observe that the expulsion of the C-tail is promoted by the displacement of a conserved arginine residue (Arg394) within the βarr polar core, which we dub “the arginine switch.” Our study uncovers a role for the arginine switch that, upon engagement, destabilizes the polar core as a crucial step in the CXCR7-induced βarr activation.


β-arrestins regulate GPCR signaling and trafficking, and adopt multiple conformational states, leading to different functional outcomes, depending of their specific interaction pattern with receptors. This study shows how receptor CXCR7 induces stepwise conformational changes in β-arrestin 2, uncovering an arginine switch mechanism that leads to its activation.

Introduction

β-arrestin1 and β-arrestin2 (referred to as βarr1 and βarr2) are multifunctional adaptor proteins that mediate the desensitization and internalization of G protein-coupled receptors (GPCRs) [14]. Upon agonist-induced activation of GPCRs, βarrs bind to the phosphorylated C-tails or intracellular loops of the receptor [510]. This leads to the recruitment of clathrin and the adaptor protein complex-2 (AP2), which triggers receptor endocytosis [11]. Subsequently, the internalized receptor can be either recycled back to the cell surface or degraded [1113]. The interaction between βarrs and clathrin/AP2 complexes is crucial for the efficient internalization of GPCRs [1,14]. The removal of GPCRs from the cell surface through βarr-mediated internalization limits the continued transmission of extracellular signals into the cell. However, despite being initially identified as proteins that desensitize GPCRs, βarrs can also interact with other signaling proteins, including mitogen-activated protein kinases [1516], Src protein kinase [17], AKT [18], and the NF-κB cascade [1921], triggering a second wave of intracellular signaling, independent of G proteins [2224]. The development of ‘biased’ drugs, which selectively modulate the activation of GPCRs to preferentially stimulate or avoid stimulating βarrs instead of G proteins, has the potential to yield improved therapeutic outcomes with enhanced safety profiles for a broad spectrum of diseases [25].

A hallmark of β-arrestin (βarr) is its remarkable structural flexibility. In response to interactions with GPCRs and small molecules, the protein can undergo a conformational transition in a process called activation [26]. βarr can assume multiple active conformations, which are linked to how it engages with the receptor and influence the functional outcome of βarr recruitment [2730]. Therefore, it is crucial to understand the molecular mechanisms governing the activation of βarrs by GPCRs.

Previous structural studies have identified both inactive and active states of βarrs. The inactive state is stabilized through the autoinhibitory binding of the βarr C-terminal tail to the N-domain of βarrs [24,3133], which prevents the inter-domain rotation between the N- and C-domains. The autoinhibitory binding of βarr C-tail to the N-domain occludes the engagement of the receptor C-tail (hereafter referred to as the Rp-tail). Thus, it has been hypothesized that the binding of Rp-tail or intracellular loops of GPCRs to the N-domain of βarrs is associated with the release of βarr C-tail from the N-domain [24,3436]. Indeed, the release of βarr C-tail from the N-domain and the subsequent inter-domain rotation have been observed in the active state of βarrs [810,26,3742].

The autoinhibitory binding of βarr C-tail to the N-domain is sustained by two distinct interfaces: the polar core and three hydrophobic elements (3E) (β-strand I and α-helix I in the N-domain and β-strand XX in the C-tail) [32,33,37,43]. The release of the βarr C-tail is a critical step in facilitating downstream signaling by exposing buried regions that are otherwise inaccessible in inactive βarr [32,44,45]. These regions include the βarr C-tail regions responsible for clathrin binding, as well as the N-domain regions of βarr that bind to scaffolding signaling kinases [14,24,46,47]. Despite the functional significance of the release of the βarr C-tail, the molecular mechanism underlying how Rp-tail binding promotes the full displacement of the βarr C-tail remains unclear due to the absence of structural information.

In this study, we aimed to unravel initial states of βarr2 activation by a Rp-tail. To achieve this, we simulated βarr2 in complex with a phosphopeptide (C7pp2) derived from the carboxyl terminus of CXCR7, an atypical chemokine receptor that interacts with βarrs but lacks functional coupling with heterotrimeric G proteins [48]. Our structural analysis suggests that C7pp2 can bind while the βarr2 C-tail remains attached to the N-domain of βarr2, with a partially disrupted polar core and other characteristics resembling its inactive state. These structural insights, together with biochemical and cell biological experiments, reveal the arginine switch mechanism and shed light on the activation mechanism of βarrs by CXCR7 C-tail.

Results

An intermediate state of βarr2

A previous study assessed the functional significance of CXCR7 phosphorylation in βarr trafficking and elucidated that a distal phospho-site cluster, PxPxxP (C7pp2, where P represents pSer/pThr and x is any other amino acid, Fig 1A), significantly contributes to βarr2 recruitment and trafficking [56]. Since βarr2 is known to be stable in an auto-inhibited basal state, where its C-tail containing β-strand XX is bound to the N-domain, we hypothesized that this auto-inhibited state could only be destabilized by sufficient phosphorylation at the GPCR Rp-tail. To verify whether the presence of 3 phosphates (pSer350, pThr352, and pSer355) in C7pp2 results in the release of βarr2 C-tail, we performed an in vitro clathrin binding assay using full-length βarr2 [57]. The clathrin binding motif of βarr2 (residues 371-379) is only accessible for clathrin binding when βarr2 C-tail is released. Our results showed that C7pp2 binding to βarr2 does not enhance clathrin binding compared to V2Rpp, a well-characterized phosphopeptide derived from the C-terminus of the vasopressin type 2 receptor [57], which effectively leads to the release of βarr2 C-tail (Fig 1B). In contrast, in the case of C7pp3, which harbors additional phosphorylations (pSer347, pSer360, and pThr361), the βarr2 C-tail is released (Fig 1B). These results indicate that the phosphorylation of C7pp2 at three sites is insufficient to fully displace the βarr2 C-tail.

Fig 1. Generating a model of the intermediate state of βarr2.

Fig 1

(A) The C-terminal sequence (residues 333-362) of CXCR7. The C7pp2 (residues 346-359) and C7pp3 (residues 346-362) peptides are indicated. Phosphorylation sites in the proximal and distal clusters (PxxPxxP and PxPxxP, where P represents pSer/pThr and x represents any other amino acid) are indicated in blue, while added phosphorylation sites on C7pp3 are denoted in red. All phosphorylated residues have been experimentally validated [4955]. (B) In vitro clathrin binding assay for βarr2. The βarr2 binding and input are shown. Clathrin binding to βarr2 was enhanced upon binding of V2Rpp and C7pp3. (C) Ribbon diagram of inactive βarr2. The C-tail of inactive βarr2 is highlighted in red. The polar core region, gate loop, and βXX motif are indicated. A zoomed-in view of the polar core region (right panel) shows an initial step of the simulation. The C-tail of βarr2 (residues 385–397) was manually displaced (shown in green) from the initial inactive conformation. The observed spontaneous inactivation of the C-tail during the simulation is indicated by a dotted arrow. (D) Representative conformations of R394 during spontaneous inactivation of the βarr2 C-tail. The frames obtained from simulations of the generated model (35 × 200 ns, restraints applied to the backbone of βarr2) were clustered based on the conformation of R394. The ensembles of the hit conformations of R394 are shown in blue (cluster I), red (cluster II), and green (cluster III), respectively. (E) The βarr2-C7pp2 complex model obtained from docking analysis. The most populated conformation of βarr2 obtained from clustering analysis was used to dock the C7pp2 peptide. (F) The representative conformations of R394 in each cluster from the simulation results. The ensembles of the hit conformations of R394 are shown in blue (cluster I) and red (cluster II). The βarr2-C7pp2 complex model obtained from docking result was used for simulations (35 × 300 ns, last 50 ns taken for analysis).

To better understand the interaction dynamics where the βarr2 C-tail is not fully displaced when bound to C7pp2, we used a sequential modeling protocol of molecular dynamics simulations. First, we simulated the re-binding of the C-tail, starting from an unbound conformation, to explore intermediate conformational states of the C-tail (35 × 200 ns, Fig 1C). Our analysis specifically focused on Arg394 within the distal C-tail, as previous experimental findings have underscored the conformational rearrangement of this residue as an important step in C-tail displacement [57]. In the inactive conformation of βarr2, Arg394 is stabilized by interactions with Asp27 and Asp299 (Fig 1C). Monitoring the distance between Arg394 and Asp299 revealed that, in the majority of the simulation replicates, we observed spontaneous inactivation of the partially displaced distal C-tail (S1 Fig and S1 Movie). Interestingly, when clustering the conformational landscape explored by Arg394 during these transition dynamics (Fig 1D), we observed a highly populated cluster (cluster I, 50%) of conformations where Arg394 is extended away from the βarr2 surface. The relatively high population of this conformation suggests that it represents an important intermediate state explored by the distal C-tail during binding/unbinding. To verify whether such a conformation can accommodate interactions with an Rp-tail, we docked the phosphorylated C7pp2 to the representative βarr structure of cluster I. Intriguingly, the docking algorithm generated a pose in which Glu358 of C7pp2 forms interactions with the partially displaced Arg394 of βarr2 (Fig 1E). Thus, our structural model suggests that Glu358 of C7pp2 stabilizes the displaced Arg394 of βarr2 and, in doing so, supports the initial stage of distal C-tail displacement in an intermediate active state of βarr2 (βarr2IM).

To further study the obtained βarr2IM-C7pp2 complex, we modeled the entire distal C-tail, which is typically not resolved in experimental structures due to its high flexibility, and carried out MD simulations for structural relaxation (Fig 1F). Intriguingly, clustering analysis of the resulting simulation runs revealed that Arg394 of βarr2 primarily adopts conformations where it maintains electrostatic interactions with Glu358 of C7pp2 (Fig 1F).

Two distinct binding motifs between βarr2IM and C7pp2

A more detailed analysis of the interface between C7pp2 and βarr2IM reveals two attachment points where C7pp2 forms polar interactions with positive residues on the βarr2IM surface, referred to as site I and site II (Fig 2A). To gain insights into the conformational flexibility of the generated complex, we conducted unrestrained MD simulations with five replicates, each running for 300 ns (S3 Fig). When analyzing individual snapshots over the simulation time, we found that the distal C-tail (blue), despite being highly flexible, stacks on top of C7pp2, thereby maintaining frequent interactions with it (S4 Fig). Additionally, we observed differences in the stability of the main contact sites I and II of C7pp2. Residues within site II explored a wider range of conformations compared to site I (S4 Fig). This variability is also reflected in the frequency of contacts established between C7pp2 and βarr2IM. For site I, we found very stable electrostatic interactions between the phosphorylated Ser350 in C7pp2 and Arg77 (81%), Arg148 (86%), and Arg166 (80%) in βarr2IM (Fig 2A). Furthermore, the phosphorylated Thr352 in C7pp2 contributes to the stability of site I by interacting with Arg166 (38%) of βarr2IM. Interestingly, for site II, our simulations revealed transient interactions between Glu358 of C7pp2 and Arg394 of βarr2IM, which can break and reform multiple times during a single simulation run, achieving a total stability of 32% within the simulation frames (Fig 2A). Despite their highly dynamic nature, the observed interactions appear to primarily converge over the course of the simulations in the studied replicates (S5 Fig).

Fig 2. Model of the intermediate βarr2-C7pp2 state.

Fig 2

(A) Structural model of the intermediate βarr2-C7pp2 complex. Interactions between C7pp2 and clusters of positive residues in βarr2 have been categorized into site I and site II, respectively. (B) ITC analysis of the binding of C7pp2 to βarr2. Purified βarr2 proteins were incubated with increasing concentrations of C7pp2 peptide, and the binding parameters were calculated based on the dose-response curve. βarr2 induces biphasic binding by C7pp2. The indicated KD1 and KD2 values correspond to site I and site II, respectively. (C) RMSF analysis of the Cα atoms of the simulated C7pp2 peptide. Residues of C7pp2 belonging to sites I or II are indicated with arrows. The data underlying the graphs shown in the figure can be found in S1 Data.

Notably, the structural model is supported by isothermal titration calorimetry (ITC) experiments (Fig 2B). In these experiments, βarr2 exhibits a biphasic binding profile with C7pp2, and fitting the data to a two-site binding model suggests that one or two C7pp2 peptides can bind to βarr2. This non-physiological 1:2 stoichiometry (receptor:βarr2 = 1:1 in cells) likely arises from the use of the isolated C-terminal peptide of CXCR7 rather than the full-length receptor. Nonetheless, the biphasic behavior clearly indicates that C7pp2 harbors two distinct binding motifs for βarr2—one that interacts at lower concentrations and another that becomes engaged only at higher concentrations during the titration. In this context, our structural model (Fig 2A) suggests that the primary ITC binding site (with higher binding affinity) corresponds to site I in our βarr2IM-C7pp2 complex, which features abundant electrostatic interactions, whereas the second ITC binding site (with significantly lower affinity) corresponds to site II. This is further supported by the RMSF profile obtained from MD simulations (Fig 2C), which reveals greater binding stability for site I (lower RMSF values) compared to site II (higher RMSF values).

To provide experimental evidence supporting our structural model, we disrupted the N-terminal and C-terminal interactions of C7pp2 with βarr2IM using R166A (site I) and R394A (site II) mutants. Remarkably, these mutations abolished the binding peaks characteristic of site I and site II, respectively (S6 Fig). Our results indicate that C7pp2 binds to βarr2 through two distinct binding events: first, the high-affinity binding of the C7pp2 N-terminus at site I (with a KD of 1.1 μM for the R394A mutant), and second, the low-affinity binding of the C7pp2 C-terminus at site II (with a KD of 16.4 μM for the R166A mutant).

To further validate the contributions of pSer350 and pThr352 in the binding of C7pp2 to βarr2IM at site I of our structural model (Fig 2A), we substituted these residues with non-phosphorylated Ser350 and Thr352 and assessed the effects of each mutation using ITC (S6 Fig). Importantly, we found that the site I binding peak was abolished, confirming the crucial role of pSer350 and pThr352 in site I binding. Taken together, we conclude that C7pp2 binds to βarr2 through two distinct binding interfaces, while the βarr2 C-tail remains attached to the N-domain of βarr2.

Partially disrupted polar core in βarr2IM by C7pp2

Notably, our structural model suggests the existence of an intermediate state with interactions between Glu358 of C7pp2 and Arg394 of the βarr2 polar core (Fig 3A). Strikingly, this structural arrangement seems to stabilize a partially displaced C-tail conformation. It is widely recognized that the polar core interactions and 3E, namely β-strand I and α-helix I in the N-domain and β-strand XX in the C-tail, play crucial roles in stabilizing the basal state of βarr2 [31,33]. Consequently, both polar core and 3E must be disrupted in an active state of βarr2, which is the current conceptual framework of GPCR-βarr2 interaction. In this respect, our structural model suggest that the polar core can be partially destabilized, while the 3E interaction remains intact (Fig 3A).

Fig 3. Destabilization of the polar core by C7pp2.

Fig 3

(A) Comparison of polar core and three-element interactions between the inactive and intermediate conformations of βarr2. The ribbon diagram of βarr2 is colored dark gray. C7pp2 and the C-tail of βarr2IM are shown in pink and green, respectively. Hydrogen bonds stabilizing the polar core interactions are shown as dashed lines. (B) Boxplots comparing the distance between D299 and R394 (forming polar interactions in the inactive βarr2) monitored within MD simulations (5 × 300 ns). Outliers are depicted as points. The significance of differences between the groups was measured using a two-sided Mann–Whitney U test. (C) CXCL12-induced trafficking of βarr2 as monitored using confocal microscopy in HEK293 cells expressing CXCR7WT and CXCR7E358A. The “Surface” images depict βarr2 localization at the plasma membrane shortly after agonist stimulation, representing initial recruitment of βarr2 to CXCR7. The “Endosomal” images show intracellular βarr2 localization at later time points, indicating receptor internalization. Scale bar is 10 μm. (D) The whole-cell ELISA-based assay to measure the surface expression of CXCR7. Data are presented as mean ± SEM of three independent experiments, normalized to CXCR7WT. (E) CXCL12-induced βarr2 recruitment to CXCR7WT and CXCR7E358A in the Tango assay. Data are presented as mean ± SEM. CXCR7E358A is significantly compromised in inducing βarr2 trafficking upon CXCL12 stimulation. The data underlying the graphs shown in the figure can be found in S1 Data.

The polar core of βarr2 in the basal state (Fig 3A) is comprised of charged residues from N-domain (Asp27 and Arg170), C-domain (Asp292 and Asp299), and C-terminal tail (Arg394), bringing different parts of βarr2 together, i.e., the N-domain, C-domain, and C-terminal tail hold together to prevent inter-domain rotation, which is a landmark structural change during βarr2 activation [43]. Among them, Arg394 points to the deep cleft between N- and C-domain, forming a central salt bridge, restrained by Asp27 (N-domain) and Asp299 (gate loop). It is interesting to note that Arg394 is the only residue that directly bridges all three parts (N-domain, C-domain, and C-terminal tail) among the five residues of the polar core.

To computationally verify the stabilizing effect of C7pp2 on the intermediate state, we monitored the integrity of the polar core by measuring the distance of Arg394 to Asp299 of βarr2IM (Fig 3B). While small values indicate an intact polar core (i.e., inactive βarr2) large distances reflect polar core disruption (i.e., intermediate βarr2). Interestingly, we find in the βarr2IM-C7pp2 complex that the polar core remains largely disrupted as indicated by an average large distance of 10 Å (Fig 3B). In contrast, when removing the C7pp2, we can observe the re-formation of a salt bridge between Arg394 to Asp299 of βarr2 in several replicates (Fig 3B, average distance 6 Å). This suggests that the binding of C7pp2, specifically the interaction of Glu358 in C7pp2 with Arg394 is a critical element to stabilize a broken polar core and in turn an intermediate βarr2 state.

To further corroborate this finding, we performed an in silico mutation of Glu358 to alanine (E358A) in the C7pp2. Remarkably, we found that this mutant also shows βarr2 inactivation in several replicates starting from a partially displaced C-tail (Fig 3B, average distance 6 Å) emphasizing the role of Glu358 of C7pp2 and Arg394 of βarr2 interactions in stabilizing the intermediate state. To experimentally verify this observation, we conducted ITC experiments, which showed that binding at site II was indeed lost in the C7pp2E358A mutant as well as in the βarr2R394A mutant (S6 Fig, lower panel).

Moreover, confocal microscopy revealed that, unlike CXCR7WT, the CXCR7E358A mutant failed to induce βarr2 redistribution from the plasma membrane to intracellular endosomes upon CXCL12 stimulation, suggesting impaired receptor internalization (Fig 3C). Additionally, the Tango assay demonstrated that CXCR7E358A exhibited a significant reduction in βarr2 recruitment in response to CXCL12, confirming that the E358A mutation disrupts βarr2 engagement and downstream trafficking (Fig 3E). While the observed loss of function does not definitively confirm the existence of an intermediate state, it does provide indirect support for the role of Glu358 in the activation process of βarr2. Altogether, these results strongly suggest that the destabilization of the polar core is initiated by the formation of a salt bridge between Glu358 of C7pp2 and Arg394 of βarr2IM.

HDX profile changes of βarr2 upon C7pp2 binding

To further study the conformational dynamics of βarr2 upon C7pp2 binding in solution, we adopted hydrogen/deuterium exchange mass spectrometry (HDX-MS) (Figs 4 and S7 and S1 Data). HDX-MS monitors the exchange between hydrogen atoms in the peptide bond backbone and deuterium in the solvent [58]. The exchange rate is affected by the conformational dynamics (i.e., exposure to the buffer and conformational flexibility) of the local area of the proteins [58]. Upon co-incubation with C7pp2, βarr2 showed increased HDX at the gate loop (Fig 4, peptides 292–302), which is likely due to the disruption of the interaction between the gate loop (Asp299) and C-tail (Arg394). Unfortunately, we could not obtain HDX-MS data from the distal C-tail region so that we could not investigate its conformational changes. However, the HDX profile of N-terminal part of βXX was increased (Fig 4, peptides 382–389) potentially due to increased conformational dynamics allosterically transmitted from the breakage between Asp299 and Arg394. This result supports our hypothesis that the disruption of the interaction between the gate loop (Asp299) and C-tail (Arg394) by C7pp2 further destabilizes β-strand XX. The HDX rates were decreased in the βVI through middle loop, lariat loop, and back loop (Fig 4, 119–133, 283–291, and 305–317). These observations raise the possibility that binding of C7pp2 to βarr2 could induce conformational rearrangements throughout the βarr2 domains. Overall, our results suggest that C7pp2 binding affects primarily parts of the βarr2 C-tail through its partial displacement as well as the dynamics of the gate loop through polar core disruption.

Fig 4. HDX profile changes of βarr2 upon co-incubation with C7pp2.

Fig 4

Regions with increased or decreased HDX upon co-incubation with C7pp2 are colored red or blue, respectively, on the structure of the βarr2IM-C7pp2 complex and the HDX profiles of the corresponding peptides are shown as graphs. Data represent the mean ± standard error of three independent experiments. Statistical analysis was performed using Student t test (*p < 0.05 compared with βarr2 alone). Differences smaller than 0.2 Da were not considered significant. The data underlying the graphs shown in the figure can be found in S1 Data.

Discussion

To activate βarr by GPCRs, interactions between GPCRs and βarr occur through two distinct interfaces. The first interface involves the binding of the receptor’s Rp-tail to the N-domain of βarr. The second interface involves the interaction between the receptor’s transmembrane helices and cytoplasmic loops, also known as the receptor core, with the central crest loops of βarr [24,34,35,59]. In this regard, there are at least three distinct binding modes between GPCRs and βarrs, which can be mediated by both the receptor core and Rp-tail, Rp-tail only, or the receptor core only. It has been demonstrated that the receptor core and Rp-tail can independently stimulate βarr activation, and these interactions trigger the release of the sequestered βarr C-tail and inter-domain rotation between the N- and C-domains [59]. One of the missing pieces of the βarr activation mechanism is how the sequestered βarr C-tail is released via interaction with GPCRs, which is considered to be the rate-limiting step [60,61].

The previously determined structures of βarr in complex with Rp-tails were limited to the inactive and active states of βarr. Consequently, it was not possible to directly observe how the polar core can be destabilized, as it was either in a stable or disrupted state in those structures. In this study, we aimed to investigate the process of initial βarr activation upon binding to the CXCR7 Rp-tail with MD simulations. The model of the intermediate state revealed several novel features that differentiate it from existing βarr structures bound to various Rp-tails, providing valuable structural insights into the activation mechanism of βarr by the receptor CXCR7 Rp-tail.

Firstly, we observed a direct binding between Glu358 of C7pp2 and Arg394 of the βarr2 C-tail. This interaction pulls the βarr C-tail away from the polar core resulting in partial disruption of the polar core through the Arg394 displacement.

Secondly, we found that C7pp2 binds to βarr2 while its C-tail remains bound to the N-domain in the proposed intermediate βarr2-C7pp2 complex. This differs from the canonical binding mode of Rp-tails, which involves the displacement of the βarr2 C-tail. As a result, we observed two distinct binding motifs between βarr2 and C7pp2, namely the canonical binding site I and the newly discovered site II, which includes the Arg394 interaction (Fig 2A). This observation is significant as it captures an intermediate activation state that cannot be observed in the existing active βarr2 structures. Consistently, the ITC results support the conclusion that the binding affinity of site I is significantly higher than that of site II, indicating that the binding of C7pp2 will occur sequentially from site I to site II (Fig 2B).

Thirdly, despite the partial disruption of the polar core, the 3E interaction is still maintained. This may be attributed to the absence of two additional phosphorylations at Ser360 and Thr361, which follow the distal phospho-site cluster PxPxxP of C7pp2 (Fig 1A). If phosphorylated Ser360 and Thr361 residues were present at the C-terminus of C7pp2, they would reside in close proximity to the 3E interaction site and disrupt it, as observed in many other active state βarr structures [37,62,63]. Indeed, V2Rpp, which possesses sufficient phosphorylation sites at its C-terminus, efficiently breaks the 3E interaction and triggers the release of βarr C-tail (Fig 1B). Consistently, the clathrin binding assay confirmed that C7pp3, which contains phosphorylations on Ser360 and Thr361 similar to V2Rpp (Fig 1A), enables the release of βarr C-tail (Fig 1B). The phosphorylations on Ser360 and Thr361 appear to be mediated by GRK2 and may have an independent role, as they differ from the proximal site phosphorylated by GRK5 or the distal site phosphorylated by both GRK2 and GRK5 [63].

Based on these results, we propose the arginine switch model, in which Arg394 binds to C7pp2 to induce βarr activation (Fig 5). In the inactive state, the arginine switch is part of the polar core, maintaining the interaction, and the βarr C-tail interacts with the N-domain through the 3E interaction. When CXCR7 Rp-tail binds to βarr through sites I and II, the arginine switch rotates and directly binds to Glu358 of CXCR7 Rp-tail, partially disrupting the polar core. This step represents an intermediate state before βarr becomes fully active, and the 3E interaction is still maintained. The phosphorylations of Ser360/Thr361 contribute to breaking the 3E interaction, leading to the release of the βarr C-tail, resulting in βarr folding into a fully active state.

Fig 5. Proposed arginine switch model for βarr2 activation by the CXCR7 Rp-tail.

Fig 5

In the inactive state, Arg394, which we name as an “arginine switch,” is an integral component of the polar core, facilitating interaction. Simultaneously, the βarr2 C-tail engages with the N-domain through a 3E interaction. Upon C7pp2 binding to βarr2, the arginine switch undergoes rotation and forms a direct interaction with Glu358 of C7pp2, leading to partial disruption of the polar core. This stage represents an intermediate state preceding βarr2 activation, where the 3E interaction remains intact. Phosphorylation of Ser360/Thr361 further contributes to the disruption of the 3E interaction, triggering the release of the βarr2 C-tail, ultimately leading to the activation of βarr2.

While our experiments elucidate the activation mechanism of βarr2 by the CXCR7 Rp-tail, further investigations will be necessary to fully understand the activation mechanism of βarr. Firstly, this study focuses on CXCR7, and whether the proposed activation mechanism applies to other GPCRs remains to be determined. Although its C-terminal tail shares similarities with other receptors, broader structural comparisons and validation using diverse GPCR phosphopeptides and MD simulations are needed to evaluate the mechanism’s general relevance. Secondly, although we explored the activation mechanism of βarr by the receptor Rp-tail, our study did not investigate the contributions of the core region of GPCR to βarr activation [7,59,64,65], thus requiring further structural studies of βarr in complex with full-length GPCR. We hypothesize that the GPCR core might also contribute to accelerating the destabilization of the polar core and 3E interactions. Alternatively, the binding of the GPCR core to βarr might trigger additional conformational changes in βarr. It is also important to underline that, although the displacement of Arg394 represents a crucial transition state in the displacement of the βarr C-tail, we cannot exclude the existence of additional transient states prior to the complete unbinding of the C-tail [66]. Thirdly, the possibility of βarr activation by phosphorylated intracellular loops of GPCRs should be considered. In the case of D2-like dopamine receptors, which have shorter C-tails compared to other GPCRs, it has been shown that phosphorylated intracellular loops can interact with βarr and trigger its activation [67,68]. Fourthly, it is necessary to investigate the biological roles of the previously characterized proximal phospho-site cluster (C7pp) [40] and the distal phospho-site cluster (C7pp2). In the case of PTH1R in living cells, βarr2 has been found to engage with both the distal phospho-site cluster and proximal phospho-site cluster, resulting in two distinct complex forms known as the tail-engaged ‘hanging’ complex and the ‘core’ complex, respectively [69]. Similarly, it is conceivable that βarr2 could adopt distinct conformations depending on the phospho-site clusters of CXCR7 while associating with the same GPCR, leading to a diverse range of functional outcomes that necessitate further investigation. Lastly, it is possible that the intermediate state of βarr may have its own functional roles in cells, extending beyond solely serving as an activation intermediate state. In a recent report, we demonstrated that the inactive state of βarr can act as a scaffold protein and mediate its functional role [70]. Therefore, uncovering the potential biological significance of this complex, if any, awaits further investigation in future studies.

As our understanding of G protein-biased or βarr-biased ligand mechanisms expands, we become increasingly aware of their potential therapeutic benefits [71]. While βarr-biased signaling produces positive effects, G protein-dependent signaling can lead to side effects, as observed with carvedilol for both β1AR and β2AR subtypes [72,73], [Sar1, D-Ala8] angiotensin II (TRV120027) for angiotensin II type 1 receptor [74], and PTH for PTH1 receptor [15]. In this case, βarr-biased ligands offer a promising avenue for the discovery of novel drugs, potentially associated with reduced side effects. Our elucidation of the βarr2-C7pp2 complex provides structural insights into the intermediate state through which βarr is activated, thus laying the foundation for pharmacological studies on βarr-biased signaling.

Materials and methods

Molecular dynamics simulation and data analysis

For MD simulation, we have started from the structure of βarr2 in an inactive conformation (PDB: 3P2D) [43]. The structure was curated, including the modeling of missing residues and protonation state assignment using the MOE package (www.chemcomp.com). To match experimental conditions, the sequence of the structure was reverted to that of a rat (Uniprot code: P29067).

To simulate rebinding of the distal C-tail (Fig 1D), we have modeled the βarr2 C-tail starting from residue 395 to residue 397 and then manually displaced the C-terminal part of the tail from the core of βarr2. Afterward, the system was simulated in 35 replicates for 200 ns, allowing the C-tail to spontaneously assume an inactive conformation (positional constraints applied to backbone atoms of βarr2 residues until residue 388, allowing C-tail flexibility). The frames were clustered using the internal algorithm in VMD [75] based on the RMSD of the Arg394 heavy atoms (cutoff 3.7).

The intermediate βarr2-C7pp2 complex was generated by docking the peptide into a representative conformation extracted from the main cluster (Fig 1D). The peptide (residues 348-359) was docked using the HADDOCK 2 web server [76]. The binding site was defined using positions within βarr2 canonically associated with GPCR C-tail binding. The final pose was selected based on scoring as well as guidelines from available βarr-C-tail complexes. Subsequently, the whole βarr2 C-tail was modeled, and the system was allowed to relax (35 × 300 ns, positional constraints applied to backbone atoms of βarr2 residues until residue 388 as well as the docked peptide backbone). Aiming to analyze only frames where the system was equilibrated, the last 50 ns of each run was taken into account. The resulting frames were clustered based on the RMSD of the Arg394 heavy atoms (cutoff 1). From these frames, we extracted a βarr2-C7pp2 conformation for subsequent simulation runs. When studying the stability of the βarr2-C7pp2 complex, as well as the impact of the E358A mutant and lack of the C7pp2 tail (Fig 3B) the systems were simulated in five replicates for 300 ns.

All generated systems were solvated (using TIP3P model water) and neutralized with NaCl ions (0.15 M concentration) using the CHARMM-GUI web server [77]. System parameters were obtained from the Charmm36M forcefield [78,79]. Simulations were carried out using Acemd3 [80]. Each system initially underwent 20 ns of equilibration in conditions of constant pressure (NPT) with positional constraints applied to the backbone atoms. For production runs, the systems were simulated in conditions of constant volume (NVT) using a 4 fs timestep. Simulations were analyzed using VMD [75]. Simulations are made available at the online GPCRmd resource [81]: (https://www.gpcrmd.org/dynadb/publications/1525/)

Cloning, protein expression, and purification

CXCR7 phosphopeptides (C7pp2 and C7pp3) for clathrin binding assay and ITC experiments were synthesized from NovoPep and Tufts University Core Facility (Fig 1A). The Rattus norvegicus wild-type βarr2 was cloned into the pET-28a expression vector and then were transformed into Escherichia coli BL21(DE3)pLysS cells (Invitrogen). Cells harboring the plasmids were grown in Luria Bertani (LB) broth containing 70 μg mL−1 chloramphenicol and 50 μg mL−1 kanamycin until the optical density (at 600 nm) reached 1.0–1.2 at 37 °C. Further, protein expression in the cells was induced by using 0.1 mM isopropyl-β-d-1-thiogalactopyranoside, after which the cells were incubated for 16 h at 16 °C.

To isolate the βarr2 protein fused to an N-terminal His6-tag, cells were collected by centrifugation at 4,000g at 4 °C for 10 min and resuspended in buffer A (20 mM Tris-HCl pH 8.0, 500 mM NaCl, and 5 mM imidazole) supplemented with 1 mM phenylmethanesulfonylfluoride. The cells were lysed by passing through a Microfluidizer (Microfluidics, Westwood, MA, USA), and the cell lysate was cleared by centrifugation. The supernatant was collected and loaded onto a Ni-sepharose affinity column (GE Healthcare, Little Chalfont, UK) and washed with buffer A. The protein was eluted using buffer A supplemented with a gradient of imidazole concentrations ranging from 100 mM to 1 M. The eluted fractions were desalted into buffer B (20 mM Tris-HCl pH 8.0 and 5 mM β-mercaptoethanol) containing 100 mM NaCl. Subsequently, further purification was carried out using affinity chromatography with a HiTrap heparin column (GE Healthcare). The proteins were eluted from the heparin column using buffer B supplemented with 1 M NaCl. To achieve further purification, eluted βarr2 was concentrated and subjected to gel filtration using a HiLoad 16/60 Superdex 200 prep-grade column (GE Healthcare). The column was pre-equilibrated with buffer B containing 200 mM NaCl and protein-containing fractions were collected. Protein was concentrated to approximately 12 mg mL−1. The protein concentration was determined by measuring the absorbance at 280 nm.

Clathrin binding assay

To evaluate the binding of clathrin to wild-type βarr2, a clathrin binding assay was conducted in the absence or presence of a 5:1 (peptide:βarr2) molar ratio of ligand (V2Rpp, C7pp2, and C7pp3). For each condition, 20 μg of βarr2 was incubated with the respective peptide in a binding buffer consisting of 20 mM Tris-HCl pH 8.0, 100 mM NaCl, and 1 mM DTT, at 4 °C for 1 h. Following the incubation, the volume of each mixture was adjusted to 100 μL using the binding buffer. Subsequently, 30 μL of GST beads, containing 30 μg of GST-clathrin, were added to the mixture, which was then agitated for 2 h at 4 °C. The GST beads with bound GST-clathrin were centrifuged at 20,000g. The beads were subsequently washed with 1 mL of the binding buffer five times. Following the washing steps, the beads were incubated with 50 μL of 25 mM GSH buffer. Clathrin binding to βarr2 was measured by Western blot analysis with an anti-his-tag mouse mAb (1:5000, MBL). Secondary antibodies used were anti-mouse IgG, HRP-linked Antibody (Cell Signaling Technology). Blots were re-probed with a GST mouse mAb (1:5000, Cell Signaling Technology) to ensure equal loading of GST-clathrin for each reaction.

Isothermal titration calorimetry (ITC)

ITC experiments were performed using Affinity ITC instruments (TA Instruments, New Castle, DE, USA) at 298 K. 200 μM of wild-type βarr2, which was prepared in a buffer containing 20 mM HEPES pH 7.0 and 200 mM NaCl was degassed at 298 K before measurements. Using a micro-syringe, 2.5 μL of 1 mM C7pp2 peptide solutions was added at intervals of 200 s to the wild-type βarr2 solution, in the cell with gentle stirring. The ITC experiments for the βarr2 mutants (R166A and R394A) and the C7pp2 mutants (C7pp2-1, C7pp2-2, and C7pp2E358A) (S6 Fig) were conducted under the same running conditions.

Surface expression assay

To study the receptor surface expression of CXCR7WT and CXCR7E358A, a whole cell-based receptor surface ELISA was performed as previously discussed [82]. Briefly, cells transiently transfected with either CXCR7WT or CXCR7E358A were seeded in a 24-well plate (corning) pre-coated with 0.01% poly-d-lysine at a density of 0.2 million cells per well and incubated at 37 °C for 24 h. After 24 h, the plate was taken out and the growth media was removed. The cells were once washed with ice-cold TBS followed by fixation with 4% Paraformaldehyde (w/v in TBS) on ice for 20 min. Thereafter, cells were washed three times (400 μL in each wash) with TBS followed by blocking with 1% BSA prepared in TBS at room temperature for 90 min. Subsequently, the cells were incubated with anti-FLAG M2-HRP (Sigma) antibody for 90 min. Antibody was prepared in 1% BSA in TBS at a dilution of 1:5,000. Following antibody incubation, cells were washed three times with 1% BSA (in TBS). Thereafter, cells were incubated with 200 μL of TMB-ELISA (Thermo Scientific) till the light blue color appeared and the signal was quenched by transferring 100 μL of colored solution to another 96-well plate containing 100 μL of 1 M H2SO4. Absorbance was measured at 450 nm using a multi-mode plate reader. For normalization of signal intensity, cell density was estimated by using a mitochondrial stain Janus green B. Afterward, TMB was removed and cells were washed two times with 200 μL of TBS. After washing, the cells were incubated for 15 min with 0.2% (w/v) Janus Green (Sigma). Excess stain was removed by washing with distilled water (three times). The stain was eluted by adding 800 μL of 0.5 N HCl per well. 200 μL of eluted solution was transferred to a 96-well plate and absorbance was recorded at 595 nm. The signal intensity was normalized by calculating the ratio of A450/A595 values. For data normalization, ratio of A450/A595 value of pcDNA transfected cells reading was considered as 1 and calculated receptor expression with respect to pcDNA. Data were analyzed by using column in GraphPad Prism software.

Confocal microscopy

For visualizing βarr2 recruitment and its trafficking, HEK293 cells were transfected with 5 µg of CXCR7WT or CXCR7E358A along with 2 µg of βarr2-mYFP mammalian constructs using a polyethylenimine reagent (21 µL) in 10 cm plates. After 6 h, the transfected HEK293 cells in FBS-deficient DMEM media were now removed and replaced with 10% FBS-supplemented DMEM media (Gibco). Post 24 h, transfected cells were trypsinized and seeded onto poly-d-lysine (Sigma) precoated glass bottom confocal dishes (GenetiX) at a density of 1 million per plate. Simultaneously, with the same transfected cells, another 24-well plate was seeded at 0.1 million per well for comparing the surface expression of CXCR7WT and CXCR7E358A. After overnight culturing the cells in confocal dishes, cells were now starved in FBS-deficient DMEM media for 4 h. Cells were visualized under the microscope and stimulated with CXCL12 (100 nM, Peprotech). Live cell microscopy was done on the cells, and images were captured at multiple time points. The instrument used was Zeiss LSM 710 NLO confocal microscope where cells were housed on a temperature and CO2-controlled platform with a motorized XY stage. A diode laser at 488 nm laser line was used for exciting mYFP, and an emitted signal was detected with a 32×array GaAsP descanned detector (Zeiss). For all experiments, microscopic settings, including laser intensity and pinhole slit were kept in the same range.

Tango assay

Tango assay measures βarr2 recruitment to the receptor. HTLA cell line, a derivative of HEK293 cell line stably expressing a tTA-dependent luciferase reporter gene and βarr2-TEV fusion gene was maintained in Dulbecco’s Minimum Essential Media supplemented with 10% FBS, 2 μg mL−1 puromycin and 100 μg ml−1 hygromycin B at 37 °C in 5% CO2. Briefly, HTLA cells at a density of 3 × 106 cells per 10 cm plate were transfected with 7 µg of CXCR7WT or CXCR7E358A constructs. After 24 h of transfection, cells were trypsinized and seeded at a density of 0.05 million cells per well in a white 96-well polystyrene micro-plate. After another 16 h, cells were stimulated with varying doses of CXCL12 (0.32 μM to 0.1 pM). The ligand concentrations were prepared in incomplete media devoid of FBS. After incubation with ligand, media was aspirated and 100 μL of luciferin (0.5 mg mL−1 in HBSS buffer) was added to each well and the plate was read for luminescence. The data was normalized with respect to the highest dose of ligand in CXCR7WT after basal correction, and then analyzed using nonlinear regression in GraphPad Prism software.

HDX-MS analysis

Wild-type βarr2 was prepared at a final concentration of 100 μM in a buffer consisting of 20 mM HEPES pH 7.4 and 150 mM NaCl. For peptide binding, 500 μM of C7pp2 was added to βarr2 and incubated at room temperature for 1 h. To initiate hydrogen/deuterium exchange, 2 μL of protein samples were mixed with 28 μL of D2O buffer (20 mM HEPES pH 7.4, 150 mM NaCl, and 10% glycerol in D2O) and incubated on ice for 10, 100, 1000, or 10 000 s. At the indicated time points, the reaction was slowed down by adding 30 μL of ice-cold quench buffer (100 mM NaH2PO4 pH 2.01). Non-deuterated samples were prepared by mixing 2 μL of the protein sample with 28 μL of H2O buffer (20 mM HEPES pH 7.4 and 150 mM NaCl in H2O) and subsequently quenching the reaction with 30 μL of ice-cold quench buffer. The quenched samples were subjected to online digestion by passing them through an immobilized pepsin column (2.1 mm × 30 mm) at a flow rate of 100 mL min−1 using 0.05% formic acid in H2O as the mobile phase at 12 °C. After the digestion process, the peptide fragments were collected on a C18 VanGuard trap column (1.7 mm × 30 mm) for desalting with 0.05% formic acid in H2O. The proteins were subsequently separated using ultra-pressure liquid chromatography on an ACQUITY UPLC C18 column (1.7 μm, 1.0 mm × 100 mm) at a flow rate of 40 mL min−1. The separation was achieved by employing an acetonitrile gradient generated by two pumps, initially starting with 8% B and gradually increasing to 85% B over a duration of 8.5 min. Mobile phase A consisted of 0.15% formic acid in H2O and mobile phase B comprised 0.15% formic acid in acetonitrile. To minimize the back exchange of deuterium to hydrogen, all components involved in the analysis, including the sample, solvents, trap, and UPLC column, were maintained at a pH of 2.5 and 0.5 °C. Mass spectral analyses were performed with a Xevo G2 QTof equipped with a standard ESI source (Waters, Milford, MA, USA). The mass spectra were acquired in the positive ion mode in the range of m/z 100–2000 for 12 min. Peptides were identified in non-deuterated samples with ProteinLynx Global Server (PLGS) 2.4 (Waters, Milford, MA, USA). The following parameters were applied: monoisotopic mass, non-specific for the enzyme while allowing up to 1 missed cleavage, MS/MS ion searches, automatic fragment mass tolerance, and automatic peptide mass tolerance. The searches were conducted with the variable methionine oxidation modification and the peptides were filtered with a peptide score of 6. To analyze the HDX-MS data, the deuterium content in each peptide was determined by measuring the centroid of the isotopic distribution using DynamX 2.0 (Waters, Milford, MA, USA). All measurements were performed in three independent experiments, and statistical significance was assessed using one-way ANOVA. Back-exchange levels were not corrected because the analyses compared different states. The details of HDX-MS data are described in S1 Data.

Supporting information

S1 Fig. Spontaneous inactivation of the C-tail observed during simulations of βarr2 with a manually displaced C-tail.

The distance between R394 and D299 (forming polar interactions in the inactive state of βarr2) monitored within MD simulations (35 × 200 ns). The data underlying the graphs shown in the figure can be found in S1 Data.

(TIF)

pbio.3003312.s001.tif (1.5MB, tif)
S2 Fig. Impact of the number of replicates on the shape and population of the R394 main cluster.

(A, B) Main cluster conformations of R394 during spontaneous inactivation (A) and Docking pose optimization (B) are shown in blue sticks. The population of each R394 cluster is indicated.

(TIF)

pbio.3003312.s002.tif (4.8MB, tif)
S3 Fig. The distance between R394 and D299 (forming polar interactions in the inactive βarr2 state) monitored within MD simulations (5 × 300 ns).

The data underlying the graphs shown in the figure can be found in S1 Data.

(TIF)

pbio.3003312.s003.tif (1.5MB, tif)
S4 Fig. Structural flexibility explored by the βarr2 C-tail (blue) and C7pp2 (red) explored in MD simulations (5 × 300 ns, 1 snapshot every 10 ns).

(TIF)

pbio.3003312.s004.tif (5.8MB, tif)
S5 Fig. Stability of polar interactions between C7pp2 and βarr2.

(A, B) The distance between residues in site I (pS350 and pT352 of C7pp2; R77, R148, and R166 of βarr2) and site II (E358 of C7pp2 and R394 of βarr2) are monitored during the whole simulation run (panel A, 5 × 300 ns) and the last 50 ns of each simulation replicate (panel B, 5 × 50 ns). For site I, the distance between the phosphorus (P) atom of the phosphorylated residues (pS350 and pT352) and the carbon atom in the guanidinium group (Cζ) of the corresponding arginine residues (R77, R148, and R166) are plotted. For site II, the distance between the Cδ atom of E358 and the Cζ atom of R394 is plotted. The data underlying the graphs shown in the figure can be found in S1 Data.

(TIF)

pbio.3003312.s005.tif (1.3MB, tif)
S6 Fig. The two binding interfaces of βarr2IM-C7pp2, including site I and site II.

ITC experiments showing the effect of mutations in the binding interfaces between βarr2 and C7pp2. The detailed sequences of C7pp2 mutants used for the ITC assay are shown in the lower right panel. Purified βarr2 was incubated with increasing peptide concentrations, and the binding parameters were calculated based on the dose-response curve. The data underlying the graphs shown in the figure can be found in S1 Data.

(TIF)

S7 Fig. Comparison of HDX-MS data of βarr2 alone and βarr2-C7pp2.

(A, B) The deuterium uptake profiles were mapped onto the structure of βarr2 (panel A) and βarr2-C7pp2 (panel B). Deuterium incorporation after 10 and 10,000 seconds of D2O buffer incubation is indicated by a color code. The color legend represents the level of deuterium uptake, and uncovered regions are shown in gray. N-terminal part of βXX region in the structure is highlighted as black dotted circle.

(TIF)

pbio.3003312.s007.tif (4.8MB, tif)
S1 Movie. Molecular dynamics simulation of the spontaneous inactivation of the βarr2 C-tail.

(MP4)

Download video file (9.4MB, mp4)
S1 Data. Data underlying figures.

(XLSX)

pbio.3003312.s009.xlsx (1.7MB, xlsx)
S1 Raw Images. Unprocessed original images for Fig 1B.

(PDF)

pbio.3003312.s010.pdf (675KB, pdf)

Acknowledgments

We thank Dr. Mithu Baidya and Parishmita Sarma from IIT Kanpur for the Tango assay.

Abbreviations

3E

three hydrophobic elements

βarr

β-arrestin

AP2

adaptor protein complex-2

CXCR7

chemokine receptor7

GPCR

G protein-coupled receptor

HDX-MS

hydrogen/deuterium exchange mass spectrometry

ITC

isothermal titration calorimetry

Data Availability

The MD simulation data will be publicly available as of the date of publication at the GPCRmd repository (www.gpcrmd.org) (https://www.gpcrmd.org/dynadb/publications/1525/).

Funding Statement

H.H.L. was supported by grants from the National Research Foundation (NRF) of Korea funded by the Korean government (2022R1A2B5B02002529 and 2022R1A5A6000760) and by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT) (RS-2024-00396026). T.M.S. was supported by resources from Sara Borrell grant CD22/00007 funded by the Institute of Health Carlos III (ISCIII), resources of grant 2021 SGR 00046 funded by Agència de Gestió d’Ajuts Universitaris i de Recerca Generalitat de Catalunya (AGAUR), and the National Center of Science, Poland, grant 2017/27/N/NZ2/02571. J.S. acknowledges funding from MICIU/AEI/10.13039/501100011033 and the ERDF/EU (grant number PID2022-137161OB-I00). J.S. acknowledges further funding from the Horizon Europe Project OBELISK under the grant agreement 101080465. K.Y.C. was supported by NRF of Korea (2021R1A2C3003518). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SS, Caron MG, et al. The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A. 1999;96(7):3712–7. doi: 10.1073/pnas.96.7.3712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Shenoy SK, Lefkowitz RJ. Multifaceted roles of beta-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J. 2003;375(3):503–15. doi: 10.1042/BJ20031076 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Lefkowitz RJ, Shenoy SK. Transduction of receptor signals by beta-arrestins. Science. 2005;308(5721):512–7. doi: 10.1126/science.1109237 [DOI] [PubMed] [Google Scholar]
  • 4.Ahn S, Shenoy SK, Luttrell LM, Lefkowitz RJ. SnapShot: β-arrestin functions. Cell. 2020;182(5):1362-1362.e1. doi: 10.1016/j.cell.2020.07.034 [DOI] [PubMed] [Google Scholar]
  • 5.Smith JS, Lefkowitz RJ, Rajagopal S. Biased signalling: from simple switches to allosteric microprocessors. Nat Rev Drug Discov. 2018;17(4):243–60. doi: 10.1038/nrd.2017.229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ. Beta-adrenergic receptor kinase: identification of a novel protein kinase that phosphorylates the agonist-occupied form of the receptor. Proc Natl Acad Sci U S A. 1986;83(9):2797–801. doi: 10.1073/pnas.83.9.2797 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Kaya AI, Perry NA, Gurevich VV, Iverson TM. Phosphorylation barcode-dependent signal bias of the dopamine D1 receptor. Proc Natl Acad Sci U S A. 2020;117(25):14139–49. doi: 10.1073/pnas.1918736117 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Huang W, Masureel M, Qu Q, Janetzko J, Inoue A, Kato HE, et al. Structure of the neurotensin receptor 1 in complex with β-arrestin 1. Nature. 2020;579(7798):303–8. doi: 10.1038/s41586-020-1953-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Staus DP, Hu H, Robertson MJ, Kleinhenz ALW, Wingler LM, Capel WD, et al. Structure of the M2 muscarinic receptor-β-arrestin complex in a lipid nanodisc. Nature. 2020;579(7798):297–302. doi: 10.1038/s41586-020-1954-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Lee Y, Warne T, Nehmé R, Pandey S, Dwivedi-Agnihotri H, Chaturvedi M, et al. Molecular basis of β-arrestin coupling to formoterol-bound β1-adrenoceptor. Nature. 2020;583(7818):862–6. doi: 10.1038/s41586-020-2419-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Marchese A, Paing MM, Temple BRS, Trejo J. G protein-coupled receptor sorting to endosomes and lysosomes. Annu Rev Pharmacol Toxicol. 2008;48:601–29. doi: 10.1146/annurev.pharmtox.48.113006.094646 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Shenoy SK, McDonald PH, Kohout TA, Lefkowitz RJ. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science. 2001;294(5545):1307–13. doi: 10.1126/science.1063866 [DOI] [PubMed] [Google Scholar]
  • 13.Hanyaloglu AC, McCullagh E, von Zastrow M. Essential role of Hrs in a recycling mechanism mediating functional resensitization of cell signaling. EMBO J. 2005;24(13):2265–83. doi: 10.1038/sj.emboj.7600688 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Goodman Jr OB, Krupnick JG, Santini F, Gurevich VV, Penn RB, Gagnon AW. Beta-arrestin acts as a clathrin adaptor in endocytosis of the beta2-adrenergic receptor. Nature. 1996;383(6599):447–50. doi: 10.1038/383447a0 [DOI] [PubMed] [Google Scholar]
  • 15.Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S. Distinct beta-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem. 2006;281(16):10856–64. doi: 10.1074/jbc.M513380200 [DOI] [PubMed] [Google Scholar]
  • 16.DeFea KA, Zalevsky J, Thoma MS, Déry O, Mullins RD, Bunnett NW. beta-arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J Cell Biol. 2000;148(6):1267–81. doi: 10.1083/jcb.148.6.1267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Luttrell LM, Ferguson SS, Daaka Y, Miller WE, Maudsley S, Della Rocca GJ, et al. Beta-arrestin-dependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science. 1999;283(5402):655–61. doi: 10.1126/science.283.5402.655 [DOI] [PubMed] [Google Scholar]
  • 18.Beaulieu J-M, Sotnikova TD, Marion S, Lefkowitz RJ, Gainetdinov RR, Caron MG. An Akt/beta-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell. 2005;122(2):261–73. doi: 10.1016/j.cell.2005.05.012 [DOI] [PubMed] [Google Scholar]
  • 19.Gao H, Sun Y, Wu Y, Luan B, Wang Y, Qu B, et al. Identification of beta-arrestin2 as a G protein-coupled receptor-stimulated regulator of NF-kappaB pathways. Mol Cell. 2004;14(3):303–17. doi: 10.1016/s1097-2765(04)00216-3 [DOI] [PubMed] [Google Scholar]
  • 20.Witherow DS, Garrison TR, Miller WE, Lefkowitz RJ. beta-Arrestin inhibits NF-kappaB activity by means of its interaction with the NF-kappaB inhibitor IkappaBalpha. Proc Natl Acad Sci U S A. 2004;101(23):8603–7. doi: 10.1073/pnas.0402851101 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wang Y, Tang Y, Teng L, Wu Y, Zhao X, Pei G. Association of beta-arrestin and TRAF6 negatively regulates Toll-like receptor-interleukin 1 receptor signaling. Nat Immunol. 2006;7(2):139–47. doi: 10.1038/ni1294 [DOI] [PubMed] [Google Scholar]
  • 22.Luttrell LM, Lefkowitz RJ. The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci. 2002;115(Pt 3):455–65. doi: 10.1242/jcs.115.3.455 [DOI] [PubMed] [Google Scholar]
  • 23.DeWire SM, Ahn S, Lefkowitz RJ, Shenoy SK. Beta-arrestins and cell signaling. Annu Rev Physiol. 2007;69:483–510. doi: 10.1146/annurev.physiol.69.022405.154749 [DOI] [PubMed] [Google Scholar]
  • 24.Asher WB, Terry DS, Gregorio GGA, Kahsai AW, Borgia A, Xie B, et al. GPCR-mediated β-arrestin activation deconvoluted with single-molecule precision. Cell. 2022;185(10):1661-1675.e16. doi: 10.1016/j.cell.2022.03.042 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Violin JD, Crombie AL, Soergel DG, Lark MW. Biased ligands at G-protein-coupled receptors: promise and progress. Trends Pharmacol Sci. 2014;35(7):308–16. doi: 10.1016/j.tips.2014.04.007 [DOI] [PubMed] [Google Scholar]
  • 26.Chen Q, Perry NA, Vishnivetskiy SA, Berndt S, Gilbert NC, Zhuo Y, et al. Structural basis of arrestin-3 activation and signaling. Nat Commun. 2017;8(1):1427. doi: 10.1038/s41467-017-01218-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Mayer D, Damberger FF, Samarasimhareddy M, Feldmueller M, Vuckovic Z, Flock T, et al. Distinct G protein-coupled receptor phosphorylation motifs modulate arrestin affinity and activation and global conformation. Nat Commun. 2019;10(1):1261. doi: 10.1038/s41467-019-09204-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Dwivedi-Agnihotri H, Chaturvedi M, Baidya M, Stepniewski TM, Pandey S, Maharana J, et al. Distinct phosphorylation sites in a prototypical GPCR differently orchestrate β-arrestin interaction, trafficking, and signaling. Sci Adv. 2020;6(37):eabb8368. doi: 10.1126/sciadv.abb8368 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Baidya M, Kumari P, Dwivedi-Agnihotri H, Pandey S, Chaturvedi M, Stepniewski TM, et al. Key phosphorylation sites in GPCRs orchestrate the contribution of β-Arrestin 1 in ERK1/2 activation. EMBO Rep. 2020;21(9):e49886. doi: 10.15252/embr.201949886 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Eiger DS, Smith JS, Shi T, Stepniewski TM, Tsai C-F, Honeycutt C, et al. Phosphorylation barcodes direct biased chemokine signaling at CXCR3. Cell Chem Biol. 2023;30(4):362-382.e8. doi: 10.1016/j.chembiol.2023.03.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hirsch JA, Schubert C, Gurevich VV, Sigler PB. The 2.8 A crystal structure of visual arrestin: a model for arrestin’s regulation. Cell. 1999;97(2):257–69. doi: 10.1016/s0092-8674(00)80735-7 [DOI] [PubMed] [Google Scholar]
  • 32.Vishnivetskiy SA, Paz CL, Schubert C, Hirsch JA, Sigler PB, Gurevich VV. How does arrestin respond to the phosphorylated state of rhodopsin? J Biol Chem. 1999;274(17):11451–4. doi: 10.1074/jbc.274.17.11451 [DOI] [PubMed] [Google Scholar]
  • 33.Vishnivetskiy SA, Schubert C, Climaco GC, Gurevich YV, Velez MG, Gurevich VV. An additional phosphate-binding element in arrestin molecule. Implications for the mechanism of arrestin activation. J Biol Chem. 2000;275(52):41049–57. doi: 10.1074/jbc.M007159200 [DOI] [PubMed] [Google Scholar]
  • 34.Kahsai AW, Pani B, Lefkowitz RJ. GPCR signaling: conformational activation of arrestins. Cell Res. 2018;28(8):783–4. doi: 10.1038/s41422-018-0067-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Scheerer P, Sommer ME. Structural mechanism of arrestin activation. Curr Opin Struct Biol. 2017;45:160–9. doi: 10.1016/j.sbi.2017.05.001 [DOI] [PubMed] [Google Scholar]
  • 36.Shukla AK, Westfield GH, Xiao K, Reis RI, Huang L-Y, Tripathi-Shukla P, et al. Visualization of arrestin recruitment by a G-protein-coupled receptor. Nature. 2014;512(7513):218–22. doi: 10.1038/nature13430 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Shukla AK, Manglik A, Kruse AC, Xiao K, Reis RI, Tseng W-C, et al. Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature. 2013;497(7447):137–41. doi: 10.1038/nature12120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Nguyen AH, Thomsen ARB, Cahill TJ 3rd, Huang R, Huang L-Y, Marcink T, et al. Structure of an endosomal signaling GPCR-G protein-β-arrestin megacomplex. Nat Struct Mol Biol. 2019;26(12):1123–31. doi: 10.1038/s41594-019-0330-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Yin W, Li Z, Jin M, Yin Y-L, de Waal PW, Pal K, et al. A complex structure of arrestin-2 bound to a G protein-coupled receptor. Cell Res. 2019;29(12):971–83. doi: 10.1038/s41422-019-0256-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Min K, Yoon H-J, Park JY, Baidya M, Dwivedi-Agnihotri H, Maharana J, et al. Crystal structure of β-arrestin 2 in complex with CXCR7 Phosphopeptide. Structure. 2020;28(9):1014-1023.e4. doi: 10.1016/j.str.2020.06.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Bous J, Fouillen A, Orcel H, Trapani S, Cong X, Fontanel S, et al. Structure of the vasopressin hormone-V2 receptor-β-arrestin1 ternary complex. Sci Adv. 2022;8(35):eabo7761. doi: 10.1126/sciadv.abo7761 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Cao C, Barros-Álvarez X, Zhang S, Kim K, Dämgen MA, Panova O, et al. Signaling snapshots of a serotonin receptor activated by the prototypical psychedelic LSD. Neuron. 2022;110(19):3154-3167.e7. doi: 10.1016/j.neuron.2022.08.006 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Zhan X, Gimenez LE, Gurevich VV, Spiller BW. Crystal structure of arrestin-3 reveals the basis of the difference in receptor binding between two non-visual subtypes. J Mol Biol. 2011;406(3):467–78. doi: 10.1016/j.jmb.2010.12.034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Nobles KN, Guan Z, Xiao K, Oas TG, Lefkowitz RJ. The active conformation of beta-arrestin1: direct evidence for the phosphate sensor in the N-domain and conformational differences in the active states of beta-arrestins1 and -2. J Biol Chem. 2007;282(29):21370–81. doi: 10.1074/jbc.M611483200 [DOI] [PubMed] [Google Scholar]
  • 45.Palczewski K, Buczyłko J, Imami NR, McDowell JH, Hargrave PA. Role of the carboxyl-terminal region of arrestin in binding to phosphorylated rhodopsin. J Biol Chem. 1991;266(23):15334–9. [PubMed] [Google Scholar]
  • 46.Gurevich VV, Gurevich EV. Arrestins: critical players in trafficking of many GPCRs. Prog Mol Biol Transl Sci. 2015;132:1–14. doi: 10.1016/bs.pmbts.2015.02.010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Kang DS, Kern RC, Puthenveedu MA, von Zastrow M, Williams JC, Benovic JL. Structure of an arrestin2-clathrin complex reveals a novel clathrin binding domain that modulates receptor trafficking. J Biol Chem. 2009;284(43):29860–72. doi: 10.1074/jbc.M109.023366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Rajagopal S, Kim J, Ahn S, Craig S, Lam CM, Gerard NP. β-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7. Proc Natl Acad Sci U S A. 2010;107(2):628–32. doi: 10.1073/pnas.0912852107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Schafer CT, Chen Q, Tesmer JJG, Handel TM. Atypical chemokine receptor 3 “Senses” CXC chemokine receptor 4 activation through GPCR kinase phosphorylation. Mol Pharmacol. 2023;104(4):174–86. doi: 10.1124/molpharm.123.000710 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Klammer M, Kaminski M, Zedler A, Oppermann F, Blencke S, Marx S, et al. Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics. 2012;11(9):651–68. doi: 10.1074/mcp.M111.016410 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Huang H, Haar Petersen M, Ibañez-Vea M, Lassen PS, Larsen MR, Palmisano G. Simultaneous enrichment of cysteine-containing peptides and phosphopeptides using a cysteine-specific phosphonate adaptable tag (CysPAT) in combination with titanium dioxide (TiO2) chromatography. Mol Cell Proteomics. 2016;15(10):3282–96. doi: 10.1074/mcp.M115.054551 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Mertins P, Mani DR, Ruggles KV, Gillette MA, Clauser KR, Wang P, et al. Proteogenomics connects somatic mutations to signalling in breast cancer. Nature. 2016;534(7605):55–62. doi: 10.1038/nature18003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Li H, Ren Z, Kang X, Zhang L, Li X, Wang Y, et al. Identification of tyrosine-phosphorylated proteins associated with metastasis and functional analysis of FER in human hepatocellular carcinoma cells. BMC Cancer. 2009;9:366. doi: 10.1186/1471-2407-9-366 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Saaber F, Schutz D, Miess E, Abe P, Desikan S, Ashok Kumar P. ACKR3 regulation of neuronal migration requires ACKR3 phosphorylation, but not β-arrestin. Cell Rep. 2019;26(6):1473-88 e9. [DOI] [PubMed] [Google Scholar]
  • 55.Zarca A, Perez C, van den Bor J, Bebelman JP, Heuninck J, de Jonker RJF, et al. Differential involvement of ACKR3 C-tail in β-arrestin recruitment, trafficking and internalization. Cells. 2021;10(3):618. doi: 10.3390/cells10030618 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Sarma P, Carino CMC, Seetharama D, Pandey S, Dwivedi-Agnihotri H, Rui X, et al. Molecular insights into intrinsic transducer-coupling bias in the CXCR4-CXCR7 system. Nat Commun. 2023;14(1):4808. doi: 10.1038/s41467-023-40482-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Xiao K, Shenoy SK, Nobles K, Lefkowitz RJ. Activation-dependent conformational changes in β-arrestin 2. J Biol Chem. 2004;279(53): 55744-53. doi: 10.1074/jbc.M409785200 [DOI] [PubMed] [Google Scholar]
  • 58.Wales TE, Engen JR. Hydrogen exchange mass spectrometry for the analysis of protein dynamics. Mass Spectrom Rev. 2006;25(1):158–70. doi: 10.1002/mas.20064 [DOI] [PubMed] [Google Scholar]
  • 59.Latorraca NR, Wang JK, Bauer B, Townshend RJL, Hollingsworth SA, Olivieri JE. Nature. 2018;557(7705):452–6. doi: 10.1038/s41586-018-0090-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Gurevich VV, Gurevich EV. The structural basis of arrestin-mediated regulation of G-protein-coupled receptors. Pharmacol Ther. 2006;110(3):465–502. doi: 10.1016/j.pharmthera.2005.09.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Pulvermüller A, Maretzki D, Rudnicka-Nawrot M, Smith WC, Palczewski K, Hofmann KP. Functional differences in the interaction of arrestin and its splice variant, p44, with rhodopsin. Biochemistry. 1997;36(30):9253–60. doi: 10.1021/bi970772g [DOI] [PubMed] [Google Scholar]
  • 62.Isaikina P, Petrovic I, Jakob RP, Sarma P, Ranjan A, Baruah M, et al. A key GPCR phosphorylation motif discovered in arrestin2⋅CCR5 phosphopeptide complexes. Mol Cell. 2023;83(12):2108-2121.e7. doi: 10.1016/j.molcel.2023.05.002 [DOI] [PubMed] [Google Scholar]
  • 63.Maharana J, Sarma P, Yadav MK, Saha S, Singh V, Saha S, et al. Structural snapshots uncover a key phosphorylation motif in GPCRs driving β-arrestin activation. Mol Cell. 2023;83(12):2091-2107.e7. doi: 10.1016/j.molcel.2023.04.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Kumari P, Srivastava A, Ghosh E, Ranjan R, Dogra S, Yadav PN, et al. Core engagement with β-arrestin is dispensable for agonist-induced vasopressin receptor endocytosis and ERK activation. Mol Biol Cell. 2017;28(8):1003–10. doi: 10.1091/mbc.E16-12-0818 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Eichel K, Jullié D, Barsi-Rhyne B, Latorraca NR, Masureel M, Sibarita J-B, et al. Catalytic activation of β-arrestin by GPCRs. Nature. 2018;557(7705):381–6. doi: 10.1038/s41586-018-0079-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Janetzko J, Deutsch J, Shi Y, Siepe DH, Masureel M, Liu W, et al. Membrane phosphoinositides allosterically tune β-arrestin dynamics to facilitate GPCR core engagement. bioRxiv. 2025;2025.06(06): 658200. 10.1101/2025.06.06.658200 [DOI] [Google Scholar]
  • 67.Lan H, Liu Y, Bell MI, Gurevich VV, Neve KA. A dopamine D2 receptor mutant capable of G protein-mediated signaling but deficient in arrestin binding. Mol Pharmacol. 2009;75(1):113–23. doi: 10.1124/mol.108.050534 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68.Clayton CC, Donthamsetti P, Lambert NA, Javitch JA, Neve KA. Mutation of three residues in the third intracellular loop of the dopamine D2 receptor creates an internalization-defective receptor. J Biol Chem. 2014;289(48):33663–75. doi: 10.1074/jbc.M114.605378 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Haider RS, Matthees ESF, Drube J, Reichel M, Zabel U, Inoue A, et al. β-arrestin1 and 2 exhibit distinct phosphorylation-dependent conformations when coupling to the same GPCR in living cells. Nat Commun. 2022;13(1):5638. doi: 10.1038/s41467-022-33307-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Yun Y, Yoon H-J, Jeong Y, Choi Y, Jang S, Chung KY, et al. GPCR targeting of E3 ubiquitin ligase MDM2 by inactive β-arrestin. Proc Natl Acad Sci U S A. 2023;120(28):e2301934120. doi: 10.1073/pnas.2301934120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71.Whalen EJ, Rajagopal S, Lefkowitz RJ. Therapeutic potential of β-arrestin- and G protein-biased agonists. Trends Mol Med. 2011;17(3):126–39. doi: 10.1016/j.molmed.2010.11.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.Wisler JW, DeWire SM, Whalen EJ, Violin JD, Drake MT, Ahn S, et al. A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling. Proc Natl Acad Sci U S A. 2007;104(42):16657–62. doi: 10.1073/pnas.0707936104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Kim I-M, Tilley DG, Chen J, Salazar NC, Whalen EJ, Violin JD, et al. Beta-blockers alprenolol and carvedilol stimulate beta-arrestin-mediated EGFR transactivation. Proc Natl Acad Sci U S A. 2008;105(38):14555–60. doi: 10.1073/pnas.0804745105 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, et al. Selectively engaging β-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther. 2010;335(3):572–9. doi: 10.1124/jpet.110.173005 [DOI] [PubMed] [Google Scholar]
  • 75.Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. J Mol Graph. 1996;14(1):33–8, 27–8. doi: 10.1016/0263-7855(96)00018-5 [DOI] [PubMed] [Google Scholar]
  • 76.van Zundert GCP, Rodrigues JPGLM, Trellet M, Schmitz C, Kastritis PL, Karaca E, et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J Mol Biol. 2016;428(4):720–5. doi: 10.1016/j.jmb.2015.09.014 [DOI] [PubMed] [Google Scholar]
  • 77.Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem. 2008;29(11):1859–65. doi: 10.1002/jcc.20945 [DOI] [PubMed] [Google Scholar]
  • 78.Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ, Mondragon-Ramirez C, et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B. 2010;114(23):7830–43. doi: 10.1021/jp101759q [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Huang J, Rauscher S, Nawrocki G, Ran T, Feig M, de Groot BL. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat Methods. 2017;14(1):71–3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 80.Harvey MJ, Giupponi G, Fabritiis GD. ACEMD: accelerating biomolecular dynamics in the microsecond time scale. J Chem Theory Comput. 2009;5(6):1632–9. doi: 10.1021/ct9000685 [DOI] [PubMed] [Google Scholar]
  • 81.Rodríguez-Espigares I, Torrens-Fontanals M, Tiemann JKS, Aranda-García D, Ramírez-Anguita JM, Stepniewski TM, et al. GPCRmd uncovers the dynamics of the 3D-GPCRome. Nat Methods. 2020;17(8):777–87. doi: 10.1038/s41592-020-0884-y [DOI] [PubMed] [Google Scholar]
  • 82.Pandey S, Kumari P, Baidya M, Kise R, Cao Y, Dwivedi-Agnihotri H, et al. Intrinsic bias at non-canonical, β-arrestin-coupled seven transmembrane receptors. Mol Cell. 2021;81(22):4605-21.e11. [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Suzanne De Bruijn

5 Nov 2024

Dear Dr Lee,

Thank you for submitting your manuscript entitled "An arginine switch drives the stepwise activation of β-arrestin" for consideration as a Research Article by PLOS Biology.

Your manuscript has now been evaluated by the PLOS Biology editorial staff as well as by an academic editor with relevant expertise and I am writing to let you know that we would like to send your submission out for external peer review.

However, before we can send your manuscript to reviewers, we need you to complete your submission by providing the metadata that is required for full assessment. To this end, please login to Editorial Manager where you will find the paper in the 'Submissions Needing Revisions' folder on your homepage. Please click 'Revise Submission' from the Action Links and complete all additional questions in the submission questionnaire.

Once your full submission is complete, your paper will undergo a series of checks in preparation for peer review. After your manuscript has passed the checks it will be sent out for review. To provide the metadata for your submission, please Login to Editorial Manager (https://www.editorialmanager.com/pbiology) within two working days, i.e. by Nov 07 2024 11:59PM.

If your manuscript has been previously peer-reviewed at another journal, PLOS Biology is willing to work with those reviews in order to avoid re-starting the process. Submission of the previous reviews is entirely optional and our ability to use them effectively will depend on the willingness of the previous journal to confirm the content of the reports and share the reviewer identities. Please note that we reserve the right to invite additional reviewers if we consider that additional/independent reviewers are needed, although we aim to avoid this as far as possible. In our experience, working with previous reviews does save time.

If you would like us to consider previous reviewer reports, please edit your cover letter to let us know and include the name of the journal where the work was previously considered and the manuscript ID it was given. In addition, please upload a response to the reviews as a 'Prior Peer Review' file type, which should include the reports in full and a point-by-point reply detailing how you have or plan to address the reviewers' concerns.

During the process of completing your manuscript submission, you will be invited to opt-in to posting your pre-review manuscript as a bioRxiv preprint. Visit http://journals.plos.org/plosbiology/s/preprints for full details. If you consent to posting your current manuscript as a preprint, please upload a single Preprint PDF.

Feel free to email us at plosbiology@plos.org if you have any queries relating to your submission.

Kind regards,

Suzanne

Suzanne De Bruijn, PhD

Associate Editor

PLOS Biology

sbruijn@plos.org

Decision Letter 1

Ines Alvarez-Garcia

16 Jan 2025

Dear Dr Lee,

Thank you for your patience while your manuscript entitled "An arginine switch drives the stepwise activation of β-arrestin" was peer-reviewed at PLOS Biology. Please also accept my sincere apologies for the long delay in sending you our decision. The manuscript has now been evaluated by the PLOS Biology editors, an Academic Editor with relevant expertise, and by three independent reviewers.

The reviews are attached below. As you will see, the reviewers find the conclusions potentially interesting, however they also raise several concerns regarding the evidence provided to support them. Reviewer 1 mentions that you should include a domain layout of barr2 with the domain and structural features discussed, and suggests also rearrangements for some of the figures. Reviewer 2 thinks that the boxplot presented is inconsistent as the conditions don’t have replicative plots and that it is not confirmed that the differences are significant. In addition, this reviewer mentions that unless further analysis of other receptor sequences and potential simulations are performed, the conclusions cannot be generalised to other GPCRs, and that there is no evidence showing that the ACKR3 and arrestin interaction is specific. Reviewer 3 raises concerning issues with the MD simulations and thinks you should provide further evidence about the convergence of the simulations. In addition, this reviewer mentions that the ITC experiments are not properly described, the Tango assay doesn’t show that the intermediate state exists and that the observed differences in the HDX experiments are too small and only observed for the first time point.

In light of the reviews and after discussing them with the Academic Editor at length, we have decided to give you a chance at addressing the concerning critiques raised by the reviewers and invite you to revise the work to thoroughly address the reviewers' reports. Please note that all the concerns should be satisfied in full and the conclusions supported in order for us to consider the manuscript further for publication. Given the extent of revision needed, we cannot make a decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is likely to be sent for further evaluation by all or a subset of the reviewers.

We expect to receive your revised manuscript within 3 months. Please email us (plosbiology@plos.org) if you have any questions or concerns, or would like to request an extension.

At this stage, your manuscript remains formally under active consideration at our journal; please notify us by email if you do not intend to submit a revision so that we may withdraw it.

**IMPORTANT - SUBMITTING YOUR REVISION**

Your revisions should address the specific points made by each reviewer. Please submit the following files along with your revised manuscript:

1. A 'Response to Reviewers' file - this should detail your responses to the editorial requests, present a point-by-point response to all of the reviewers' comments, and indicate the changes made to the manuscript.

*NOTE: In your point-by-point response to the reviewers, please provide the full context of each review. Do not selectively quote paragraphs or sentences to reply to. The entire set of reviewer comments should be present in full and each specific point should be responded to individually, point by point.

You should also cite any additional relevant literature that has been published since the original submission and mention any additional citations in your response.

2. In addition to a clean copy of the manuscript, please also upload a 'track-changes' version of your manuscript that specifies the edits made. This should be uploaded as a "Revised Article with Changes Highlighted" file type.

3. Resubmission Checklist

When you are ready to resubmit your revised manuscript, please refer to this resubmission checklist: https://plos.io/Biology_Checklist

To submit a revised version of your manuscript, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' where you will find your submission record.

Please make sure to read the following important policies and guidelines while preparing your revision and fulfil the editorial requests:

a) *PLOS Data Policy*

Please note that as a condition of publication PLOS' data policy (http://journals.plos.org/plosbiology/s/data-availability) requires that you make available all data used to draw the conclusions arrived at in your manuscript. If you have not already done so, you must include any data used in your manuscript either in appropriate repositories, within the body of the manuscript, or as supporting information (N.B. this includes any numerical values that were used to generate graphs, histograms etc.). Please also indicate in each figure legend where the data can be found. For an example see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5

b) *Published Peer Review*

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://blogs.plos.org/plos/2019/05/plos-journals-now-open-for-published-peer-review/

c) *Blot and Gel Data Policy*

Please provide the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare them now, if you have not already uploaded them. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

d) *Blurb*

Please also provide a blurb which (if accepted) will be included in our weekly and monthly Electronic Table of Contents, sent out to readers of PLOS Biology, and may be used to promote your article in social media. The blurb should be about 30-40 words long and is subject to editorial changes. It should, without exaggeration, entice people to read your manuscript. It should not be redundant with the title and should not contain acronyms or abbreviations. For examples, view our author guidelines: https://journals.plos.org/plosbiology/s/revising-your-manuscript#loc-blurb

e) *Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosbiology/s/submission-guidelines#loc-materials-and-methods

Thank you again for your submission to our journal. We hope that our editorial process has been constructive thus far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Ines

--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

ialvarez-garcia@plos.org

----------------------------------------------

Reviewers' comments

Rev. 1: Jennifer Cash – note that this reviewer has signed her review.

This manuscript describes an intermediate state in the activation of barr2 through binding the phosphorylated C-terminal tail of a GPCR using molecular dynamics simulations, ITC, a cell-based assay, and HDX-MS. Specifically, the authors are interested in examining how the sequestered barr2 C-terminal tail, which binds the N-domain and stabilizes the inactive state, is released upon interaction with GPCRs. Previous structural data has been limited to the active and inactive states of barr, leaving the mechanisms occurring in the intermediate states unknown. Using MD, the authors find that a peptide representing a phosphorylated GPCR C-terminal tail binds to barr2 while the barr2 C-tail is still bound to the N-domain in an intermediate state, identifying a previously unrecognized binding mode. The manuscript is well-written and appears overall technically sound. I have the following suggestions to improve the presentation and interpretability of the data:

* I recommend including a domain layout of barr2 with the domain and structural features discussed in the manuscript highlighted.

* Line 106-107, how do the authors know that C7pp2 is binding and inducing an intermediate state? This seems like a jump in rationale.

* In figure 1C, I would recommend not coloring the aspartate sidechains red, or coloring the oxygens a different shade of red.

* In the legend for figure 3, please include information on the statistical analysis that was performed and significance.

* I suggest moving figure S5 into the main text. I find it to be much more informative and clear with regards to following the text than current figure 3A. If 3A was replaced and 3B made smaller, I think S5 would fit within 3.

* In figure 3C, what does "surface" and "endosomal" refer to? How are these treatments different? This information should be included either in the figure legend or the results section. Some description of the assays used in figure 3C-E should be included in the results section (lines 212-216) to help the reader understand why these assays were used.

* The results section describing the HDX-MS data needs further explanation. Why could data not be obtained on the distal C-tail region? This could signify that something is wrong with the sample, unless further information indicating otherwise is provided. Is the 382-389 region the only part of this tail that data could be obtained on? I would recommend that the authors also show the complete HDX-MS data showing the overall dynamics of barr2 and the peptide plotted onto each structure (alone and in complex, either one chosen time point or an average), for completeness and show this in the supplemental. Per peptide deuterium uptake levels are shown in an Excel file in the supplemental, but it is not easy for the reader to interpret the overall dynamics of barr2 by looking at this. Also, what is the relevance of the decreased exchange rates in the middle loop, lariat loop, and back loop? These features are not discussed elsewhere in the text. Please include a discussion of this.

* I like the mechanistic model in figure 5 - well done!

Rev. 2:

In the manuscript entitled "An arginine switch drives the stepwise activation of β-arrestin" by Jeong Seok Ji, et al. the authors use molecular dynamics, ITC binding assays, fluorescence microscopy, and HDX experiments to describe an interaction between β-arrestin and a phosphopeptide of ACKR3 that they claim is important for the activation of β-arrestins. The paper does a good job of characterizing this interaction and providing multiple sources to support the importance of a conserved arginine residue (R394) and its role in destabilizing the polar core and subsequent releasing of the C-terminal tail to allow for β-arrestin activation. While the authors describe a mechanism for the binding of the ACKR3 C-terminal peptide to β-arrestin2 (namely a glutamate residue in the C-terminus of ACKR3 that they propose interacts with R394 of β-arrestin2) they fall short in relating this broadly to GPCRs at large. While the introduction and discussion sections are framed in terms of general mechanisms for arrestin activation by GPCRs, no analysis is done to assess the presence of comparable residues or motifs in other GPCR C-terminal sequences. This omission must be addressed to justify any discussion of general GPCR/arrestin activation mechanisms.

Major comments

* What is V2Rpp? It is never described, and its relevance to the ACKR3 peptides that are the focus of the study create confusion at the outset that is never resolved.

* Page 11, Lines 33-35 "Our study uncovers a previously unknown molecular switch that, upon engagement, destabilizes the polar core as a crucial step in the GPCR-induced βarr activation.": While the findings in this paper do expand on the importance of a conserved arginine residue in β-arrestins, I would hardly say this was a previously unknown molecular switch. The authors themselves stated "Our analysis specifically focused on Arg394 within the distal C-tail, as previous experimental findings have underscored the conformational rearrangement of this residue as an important step in C-tail displacement50 ".

* Figure 3B - The data shown on the boxplot is inconsistent. All conditions should have replicate points shown as with the first condition (red box). Additionally, some significance analysis could be done between these conditions to convince the reader that these differences are meaningful as the replicates from the WT conditions seem to span the entire range, albeit slightly skewed to the upper distances.

* Page 22, Line 290 "While our experiments elucidate the activation mechanism of βarr2 by the receptor Rp-tail": The paper describes a potential activation mechanism for the ACKR3 C-terminal peptide and β-arrestin2. This does not necessarily apply broadly to other GPCRs and further analysis of other receptor sequences and potential simulations would have to be done to make this claim. ACKR3 is intrinsically biased toward arrestin, and the authors offer no evidence that this interaction isn't unique to ACKR3. I don't particularly think this is unique to ACKR3 as only the C-terminus was used and it's not particularly different from other GPCRs, but the authors don't even mention this potential pitfall, and this leaves the central claim with some doubt.

Minor Comments

* Page 11, Lines 29-30 "we reveal how specific interactions with a prototypical GPCR": ACKR3 is not a "prototypical" GPCR. It doesn't couple to G-proteins and is intrinsically arrestin biased. The A stands for atypical.

* Page 12, Lines 44-46 "The removal of GPCRs from the cell surface through βarr-mediated internalization prevents them from transmitting extracellular signals into cells.": This sentence is followed by a contradictory statement and should be revised to clarify and harmonize the intended meaning (e.g. "continued transmission of extracellular")

* Page 16, Lines 151-154 "Notably, the structural model is supported by isothermal titration calorimetry (ITC) experiments (Fig. 2B). In ITC, βarr2 exhibits a biphasic binding pattern with C7pp2, and data fitting to a two-site binding model indicates that C7pp2 contains two distinct binding motifs for βarr2.": Fitting values (KD values) are not shown in the text or in Figure 2B and should be added. KD values are shown in the supplement for other ITC conditions.

* Figure 3A - Side chains should match the corresponding ribbon colors as in Figure 2.

Rev. 3:

This manuscript by Ji and coworkers describes a combination of molecular dynamics simulations (MD), biochemical and cell-based experiments to elucidate the activation mechanism of β-arrestin.

Arrestin activation occurs by the binding of the phosphorylated tail or intracellular loops of G protein-coupled receptors (GPCRs). The structures of β-arrestins (also called arrestin2 and arrestin3) in complex with phosphorylated GPCRs or respective phosphopeptides have been elucidated and show that the phosphopeptide forms an intramolecular beta-sheet with arrestin strand beta-1. The peptide thereby replaces arrestin beta-strand 20, which in (inactive) apo arrestin forms an intramolecular beta-sheet with strand beta-1. As a consequence, beta-20 and the entire C-terminus are released from the arrestin core, the arrestin N- and C-domains rotate slightly against each other and the arrestin loop conformations change.

While this activated state is known, it is unclear whether the binding of the peptide occurs via intermediate steps. To elucidate such intermediate steps, the authors use mostly a shortened version of a phosphopeptide derived from the carboxyl terminus of CXCR7, C7pp2, to study the interactions with βarr2. C7pp lacks the last three residues STK of the C-tail, two of which (ST) can also be phosphorylated. A second peptide C7pp3 comprises these residues. The authors carry out MD simulations as well as biochemical and cellular experiments, from which they claim that the C7pp2 peptide displaces as a first step R394 while still keeping the beta-20.beta-1 sheet intact. This would then be an intermediate step during arrestin activation.

However, as indicated below, this evidence is not solid and the reasoning is flawed. For this reason, I cannot recommend this manuscript for publication.

In detail:

1. MD simulations: the MD simulations were carried out for sets of 7 x 300 ns or 5 x 200 ns. This is much too short to follow a beta-strand release or replacement from a beta-sheet. Typical opening times of individual beta-hairpins are on the order of at least 10 microseconds. The authors give no evidence about the convergence of their simulations. Thus, it is unclear what to conclude much from any of the MD results.

2. ITC experiments: Fig. 2B shows a biphasic ITC profile. The horizontal axis is not labeled. I assume it is the molar ratio. No stoichiometry is indicated. The biphasic behavior is used as evidence for a two-site (step-wise) binding mechanism. However, this does not make sense. If the horizontal axis is indeed the molar ratio, then the reaction would give two C7pp2 peptides bound to one βarr2 molecule. How can this be? A GPCR has only one tail. The experiment also lacks a description how the fit curve was obtained. Such a biphasic fit must involve a 2:1 chemical reaction.

3. Tango assay (Fig. 3 C-E): the assay shows that CXCR7-E354 is important for βarr2 recruitment, but not more. I.e. it does not give evidence that the claimed intermediate state exists.

4. HDX experiments (Fig. 4): The observed differences between C7pp2-bound and -free βarr2 are in general very small. The claimed significant differences for decreased exchange (blue asterisks) are particularly small and are observed only for the first time point, which may be an experimental variation after mixing. More importantly as indicated in the methods 2 μL of protein samples were mixed with 28 μL of D2O buffer. So, the final deuterium uptake should be 1-2/28 = 93%. However, the uptake is maximally 60% and varies strongly between the detected stretches albeit saturation seems to be achieved. This is completely unclear. As a small additional point, it is also unclear what the following sentence in the figure legend means 'Differences smaller than 0.2 Da were not considered significant.'

Decision Letter 2

Ines Alvarez-Garcia

22 May 2025

Dear Dr Lee,

Thank you for your patience while we considered your revised manuscript "An arginine switch drives the stepwise activation of β-arrestin by CXCR7" for publication as a Research Article at PLOS Biology. This revised version of your manuscript has been evaluated by the PLOS Biology editors, the Academic Editor and one of the original reviewers. The Academic Editor also checked your responses to the other reviewers.

Based on the review and on our Academic Editor's assessment of your revision, we are likely to accept this manuscript for publication, provided you satisfactorily address the data and other policy-related requests stated below my signature.

As you address these items, please take this last chance to review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the cover letter that accompanies your revised manuscript.

In addition to these revisions, you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests shortly.

We expect to receive your revised manuscript within two weeks.

To submit your revision, please go to https://www.editorialmanager.com/pbiology/ and log in as an Author. Click the link labelled 'Submissions Needing Revision' to find your submission record. Your revised submission must include the following:

- a cover letter that should detail your responses to any editorial requests, if applicable, and whether changes have been made to the reference list

- a Response to Reviewers file that provides a detailed response to the reviewers' comments (if applicable, if not applicable please do not delete your existing 'Response to Reviewers' file.)

- a track-changes file indicating any changes that you have made to the manuscript.

NOTE: If Supporting Information files are included with your article, note that these are not copyedited and will be published as they are submitted. Please ensure that these files are legible and of high quality (at least 300 dpi) in an easily accessible file format. For this reason, please be aware that any references listed in an SI file will not be indexed. For more information, see our Supporting Information guidelines:

https://journals.plos.org/plosbiology/s/supporting-information

*Published Peer Review History*

Please note that you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. Please see here for more details:

https://plos.org/published-peer-review-history/

*Press*

Should you, your institution's press office or the journal office choose to press release your paper, please ensure you have opted out of Early Article Posting on the submission form. We ask that you notify us as soon as possible if you or your institution is planning to press release the article.

*Protocols deposition*

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

Please do not hesitate to contact me should you have any questions.

Sincerely,

Ines

--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

ialvarez-garcia@plos.org

------------------------------------------------------------------------

DATA POLICY: IMPORTANT - PLEASE READ

You may be aware of the PLOS Data Policy, which requires that all data be made available without restriction: http://journals.plos.org/plosbiology/s/data-availability. For more information, please also see this editorial: http://dx.doi.org/10.1371/journal.pbio.1001797

Note that we do not require all raw data. Rather, we ask that all individual quantitative observations that underlie the data summarized in the figures and results of your paper be made available in one of the following forms:

1) Supplementary files (e.g., excel). Please ensure that all data files are uploaded as 'Supporting Information' and are invariably referred to (in the manuscript, figure legends, and the Description field when uploading your files) using the following format verbatim: S1 Data, S2 Data, etc. Multiple panels of a single or even several figures can be included as multiple sheets in one excel file that is saved using exactly the following convention: S1_Data.xlsx (using an underscore).

2) Deposition in a publicly available repository. Please also provide the accession code or a reviewer link so that we may view your data before publication.

Regardless of the method selected, please ensure that you provide the individual numerical values that underlie the summary data displayed in the following figure panels as they are essential for readers to assess your analysis and to reproduce it:

Fig. 2B, C; Fig. 3B, D, E; Fig. 4; Fig. S1; Fig. S3; Fig. S5A, B and Fig. S6

NOTE: the numerical data provided should include all replicates AND the way in which the plotted mean and errors were derived (it should not present only the mean/average values).

Please also ensure that figure legends in your manuscript include information on WHERE THE UNDERLYING DATA CAN BE FOUND, and ensure your supplemental data file/s has a legend.

Please ensure that your Data Statement in the submission system accurately describes where your data can be found.

------------------------------------------------------------------------

CODE POLICY

Per journal policy, if you have generated any custom code during the course of this investigation, please make it available without restrictions. Please ensure that the code is sufficiently well documented and reusable, and that your Data Statement in the Editorial Manager submission system accurately describes where your code can be found.

Please note that we cannot accept sole deposition of code in GitHub, as this could be changed after publication. However, you can archive this version of your publicly available GitHub code to Zenodo. Once you do this, it will generate a DOI number, which you will need to provide in the Data Accessibility Statement (you are welcome to also provide the GitHub access information). See the process for doing this here: https://docs.github.com/en/repositories/archiving-a-github-repository/referencing-and-citing-content

------------------------------------------------------------------------

BLOT AND GEL REPORTING REQUIREMENTS:

We require the original, uncropped and minimally adjusted images supporting all blot and gel results reported in an article's figures or Supporting Information files. We will require these files before a manuscript can be accepted so please prepare and upload them now - we require the original gels for Fig. 1B. Please carefully read our guidelines for how to prepare and upload this data: https://journals.plos.org/plosbiology/s/figures#loc-blot-and-gel-reporting-requirements

------------------------------------------------------------------------

Reviewers' comments

Rev. 2:

The authors provide thorough and extensive responses to the comments raised by the reviewers which significantly improve the clarity of the manuscript. No additional comments or concerns.

Decision Letter 3

Ines Alvarez-Garcia

11 Jul 2025

Dear Dr Lee,

Thank you for the submission of your revised Research Article entitled "An arginine switch drives the stepwise activation of β-arrestin by CXCR7" for publication in PLOS Biology. On behalf of my colleagues and the Academic Editor, Carole Parent, I am delighted to let you know that we can in principle accept your manuscript for publication, provided you address any remaining formatting and reporting issues. These will be detailed in an email you should receive within 2-3 business days from our colleagues in the journal operations team; no action is required from you until then. Please note that we will not be able to formally accept your manuscript and schedule it for publication until you have completed any requested changes.

Please take a minute to log into Editorial Manager at http://www.editorialmanager.com/pbiology/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production process.

PRESS

We frequently collaborate with press offices. If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximise its impact. If the press office is planning to promote your findings, we would be grateful if they could coordinate with biologypress@plos.org. If you have previously opted in to the early version process, we ask that you notify us immediately of any press plans so that we may opt out on your behalf.

We also ask that you take this opportunity to read our Embargo Policy regarding the discussion, promotion and media coverage of work that is yet to be published by PLOS. As your manuscript is not yet published, it is bound by the conditions of our Embargo Policy. Please be aware that this policy is in place both to ensure that any press coverage of your article is fully substantiated and to provide a direct link between such coverage and the published work. For full details of our Embargo Policy, please visit http://www.plos.org/about/media-inquiries/embargo-policy/.

Many congratulations and thanks again for choosing PLOS Biology for publication and supporting Open Access publishing. We look forward to publishing your study. 

Sincerely, 

Ines

--

Ines Alvarez-Garcia, PhD

Senior Editor

PLOS Biology

ialvarez-garcia@plos.org

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Spontaneous inactivation of the C-tail observed during simulations of βarr2 with a manually displaced C-tail.

    The distance between R394 and D299 (forming polar interactions in the inactive state of βarr2) monitored within MD simulations (35 × 200 ns). The data underlying the graphs shown in the figure can be found in S1 Data.

    (TIF)

    pbio.3003312.s001.tif (1.5MB, tif)
    S2 Fig. Impact of the number of replicates on the shape and population of the R394 main cluster.

    (A, B) Main cluster conformations of R394 during spontaneous inactivation (A) and Docking pose optimization (B) are shown in blue sticks. The population of each R394 cluster is indicated.

    (TIF)

    pbio.3003312.s002.tif (4.8MB, tif)
    S3 Fig. The distance between R394 and D299 (forming polar interactions in the inactive βarr2 state) monitored within MD simulations (5 × 300 ns).

    The data underlying the graphs shown in the figure can be found in S1 Data.

    (TIF)

    pbio.3003312.s003.tif (1.5MB, tif)
    S4 Fig. Structural flexibility explored by the βarr2 C-tail (blue) and C7pp2 (red) explored in MD simulations (5 × 300 ns, 1 snapshot every 10 ns).

    (TIF)

    pbio.3003312.s004.tif (5.8MB, tif)
    S5 Fig. Stability of polar interactions between C7pp2 and βarr2.

    (A, B) The distance between residues in site I (pS350 and pT352 of C7pp2; R77, R148, and R166 of βarr2) and site II (E358 of C7pp2 and R394 of βarr2) are monitored during the whole simulation run (panel A, 5 × 300 ns) and the last 50 ns of each simulation replicate (panel B, 5 × 50 ns). For site I, the distance between the phosphorus (P) atom of the phosphorylated residues (pS350 and pT352) and the carbon atom in the guanidinium group (Cζ) of the corresponding arginine residues (R77, R148, and R166) are plotted. For site II, the distance between the Cδ atom of E358 and the Cζ atom of R394 is plotted. The data underlying the graphs shown in the figure can be found in S1 Data.

    (TIF)

    pbio.3003312.s005.tif (1.3MB, tif)
    S6 Fig. The two binding interfaces of βarr2IM-C7pp2, including site I and site II.

    ITC experiments showing the effect of mutations in the binding interfaces between βarr2 and C7pp2. The detailed sequences of C7pp2 mutants used for the ITC assay are shown in the lower right panel. Purified βarr2 was incubated with increasing peptide concentrations, and the binding parameters were calculated based on the dose-response curve. The data underlying the graphs shown in the figure can be found in S1 Data.

    (TIF)

    S7 Fig. Comparison of HDX-MS data of βarr2 alone and βarr2-C7pp2.

    (A, B) The deuterium uptake profiles were mapped onto the structure of βarr2 (panel A) and βarr2-C7pp2 (panel B). Deuterium incorporation after 10 and 10,000 seconds of D2O buffer incubation is indicated by a color code. The color legend represents the level of deuterium uptake, and uncovered regions are shown in gray. N-terminal part of βXX region in the structure is highlighted as black dotted circle.

    (TIF)

    pbio.3003312.s007.tif (4.8MB, tif)
    S1 Movie. Molecular dynamics simulation of the spontaneous inactivation of the βarr2 C-tail.

    (MP4)

    Download video file (9.4MB, mp4)
    S1 Data. Data underlying figures.

    (XLSX)

    pbio.3003312.s009.xlsx (1.7MB, xlsx)
    S1 Raw Images. Unprocessed original images for Fig 1B.

    (PDF)

    pbio.3003312.s010.pdf (675KB, pdf)
    Attachment

    Submitted filename: Authors_ response to reviewers_ comments_20250415_002.docx

    pbio.3003312.s013.docx (4.7MB, docx)
    Attachment

    Submitted filename: Authors__response_to_reviewers__comments_20250415_002_auresp_3.docx

    pbio.3003312.s014.docx (4.7MB, docx)

    Data Availability Statement

    The MD simulation data will be publicly available as of the date of publication at the GPCRmd repository (www.gpcrmd.org) (https://www.gpcrmd.org/dynadb/publications/1525/).


    Articles from PLOS Biology are provided here courtesy of PLOS

    RESOURCES